Abstract
Background: The management of acute agitation in patients with bipolar disorder or schizophrenia is a multifaceted and dynamic task, which presents unique and complex challenges to healthcare providers.
Objective: To ascertain and describe which medications are best to use in patients with agitation, affected by bipolar disorder or schizophrenia.
Method: Selective review of current literature and guidelines referred to the treatment of agitation in individuals affected with bipolar disorder or schizophrenia
Results: When possible, the pharmacologic management of agitation should be preceded by a in-depth evaluation of the possible causes of the agitation. The use for of first and second-generation antipsychotic medications, of benzodiazepines and of the newer inhaled antipsychotic loxapine, is reviewed and commented.
Conclusion: The mainstay of medication treatment of acute agitation should be based on a thotough assessment cause. If agitation is due to delirium or to another physial condition, an attempt to address the underlying causes should be always considered. When agitation is primarily due to schizophrenia or bipolar disorder, antipsychotics and/or benzodiazepines are usually the mainstay of treatment. Newer inhaled formulation of loxapine has shown ability to rapidly reduce the agitation in mild to moderate patients with schizophrenia or bipolar disorder, with a decrease in agitation that was evident since the first assessment, 10 minutes after the first dose.
Keywords: Agitation, bipolar, schizophrenia, antipsychotics, benzodiazepines, loxapine, intramuscular, oral, inhaled.
CNS & Neurological Disorders - Drug Targets
Title:Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia
Volume: 16 Issue: 8
Author(s): Giovanni Amodeo*, Andrea Fagiolini, Gabriele Sachs and Andreas Erfurth
Affiliation:
- Department of Molecular Medicine, University of Siena School of Medicine, Viale Bracci 1, Siena 53100,Italy
Keywords: Agitation, bipolar, schizophrenia, antipsychotics, benzodiazepines, loxapine, intramuscular, oral, inhaled.
Abstract: Background: The management of acute agitation in patients with bipolar disorder or schizophrenia is a multifaceted and dynamic task, which presents unique and complex challenges to healthcare providers.
Objective: To ascertain and describe which medications are best to use in patients with agitation, affected by bipolar disorder or schizophrenia.
Method: Selective review of current literature and guidelines referred to the treatment of agitation in individuals affected with bipolar disorder or schizophrenia
Results: When possible, the pharmacologic management of agitation should be preceded by a in-depth evaluation of the possible causes of the agitation. The use for of first and second-generation antipsychotic medications, of benzodiazepines and of the newer inhaled antipsychotic loxapine, is reviewed and commented.
Conclusion: The mainstay of medication treatment of acute agitation should be based on a thotough assessment cause. If agitation is due to delirium or to another physial condition, an attempt to address the underlying causes should be always considered. When agitation is primarily due to schizophrenia or bipolar disorder, antipsychotics and/or benzodiazepines are usually the mainstay of treatment. Newer inhaled formulation of loxapine has shown ability to rapidly reduce the agitation in mild to moderate patients with schizophrenia or bipolar disorder, with a decrease in agitation that was evident since the first assessment, 10 minutes after the first dose.
Export Options
About this article
Cite this article as:
Amodeo Giovanni*, Fagiolini Andrea, Sachs Gabriele and Erfurth Andreas, Older and Newer Strategies for the Pharmacological Management of Agitation in Patients with Bipolar Disorder or Schizophrenia, CNS & Neurological Disorders - Drug Targets 2017; 16 (8) . https://dx.doi.org/10.2174/1871527316666170919115507
DOI https://dx.doi.org/10.2174/1871527316666170919115507 |
Print ISSN 1871-5273 |
Publisher Name Bentham Science Publisher |
Online ISSN 1996-3181 |
Call for Papers in Thematic Issues
Diagnosis and treatment of central nervous system infectious diseases
Infectious diseases of the central nervous system (CNS) can be divided into bacterial, tuberculous, viral, fungal, parasitic infections, etc. Early etiological treatment is often the most crucial means to reduce the mortality rate of patients with central nervous system infections, reduce complications and sequelae, and improve prognosis. The initial clinical ...read more
Techniques of Drug Repurposing: Delivering a new life to Herbs & Drugs
Of late, with the adaptation of innovative approaches and integration of advancements made towards medical sciences as well as the availability of a wide range of tools; several therapeutic challenges are being translated into viable clinical solutions, with a high degree of efficacy, safety, and selectivity. With a better understanding ...read more
Trends and perspectives in the rational management of CNS disorders
Central nervous system (CNS) diseases enforce a significant global health burden, driving ongoing efforts to improve our understanding and effectiveness of therapy. This issue investigates current advances in the discipline, focusing on the understanding as well as therapeutic handling of various CNS diseases. The issue covers a variety of diseases, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Xanthine Derivatives in the Heart: Blessed or Cursed?
Current Medicinal Chemistry Monoclonal Antibodies in the Treatment of Systemic Lupus Erythematosus
Current Drug Targets Calcium Channel Subtypes and Exocytosis in Chromaffin Cells at Early Life
Current Molecular Pharmacology Development and Characterization of Cassia grandis and Bixa orellana Nanoformulations
Current Topics in Medicinal Chemistry Biochemical Markers for Brain Injury Monitoring in Children with or without Congenital Heart Diseases
CNS & Neurological Disorders - Drug Targets Cytokine and Nitric Oxide Production Following Severe Envenomation
Current Drug Targets - Inflammation & Allergy Ganoderma lucidum: A Potential for Biotechnological Production of Anti-Cancer and Immunomodulatory Drugs
Recent Patents on Anti-Cancer Drug Discovery Ag/CdS Nanocomposite: An Efficient Recyclable Catalyst for the Synthesis of Novel 8-Aryl-8H-[1,3]dioxolo[4,5-g]chromene-6-carboxylic Acids under Mild Reaction Conditions
Combinatorial Chemistry & High Throughput Screening Hypertension in Chronic Kidney Disease: Novel Insights
Current Hypertension Reviews The Activated Endocannabinoid System in Atherosclerosis: Driving Force or Protective Mechanism?
Current Drug Targets Identification of L-Amino Acid Oxidase (Mb-LAAO) with Antibacterial Activity in the Venom of Montivipera bornmuelleri, a Viper from Lebanon
Infectious Disorders - Drug Targets Targeting TNF-Alpha to Elucidate and Ameliorate Neuroinflammation in Neurodegenerative Diseases
CNS & Neurological Disorders - Drug Targets Endocannabinoid Blockade and the Cardiovascular System
Current Drug Therapy Adoptive Immunotherapy for B-cell Malignancies Using CD19- Targeted Chimeric Antigen Receptor T-Cells: A Systematic Review of Efficacy and Safety
Current Medicinal Chemistry COVID-19 Invades Several Important Organs other than the Lungs: Organs Crosstalk
Coronaviruses Medicinal Properties of the Jamaican Pepper Plant Pimenta dioica and Allspice
Current Drug Targets “PARG Inhibitors’ Success: A Long Way to Go!”
Current Enzyme Inhibition Torasemide in Hypertension and Heart Failure: Re-inventing Loop Diuretic Therapy?
Current Pharmaceutical Design Compendious Review on Bioactive Constituents and Pharmacotherapeutic Profile of Heliotropium indicum Linn
The Natural Products Journal PDE5 Inhibitors: In Vitro and In Vivo Pharmacological Profile
Current Pharmaceutical Design